Current guidelines for cervical cancer screening
- PMID: 22735065
- DOI: 10.1111/j.1745-7599.2012.00704.x
Current guidelines for cervical cancer screening
Abstract
Purpose: To provide evidence-based information that will guide nurse practitioners in instituting the most current cervical cancer screening recommendations.
Data sources: A literature search covering the years 2006 to the present conducted through Medline, CINAHL, and OVID.
Conclusions: Human papillomavirus (HPV) cervical infections are highly prevalent among females under 21 years, yet this age group has a low incidence of cervical cancer. For young women, 90% of HPV infections regress in 24 months, and, in longitudinal studies, no invasive cervical cancer was detected. HPV co-testing is effective for women age 30 and over.
Implications for practice: Current scientific evidence supports initiating cervical cancer screening for immunocompetent women at age 21, biennial screening between ages 21 and 29, and HPV DNA co-testing for women over 30. Nurse practitioners play an important role in integrating the newest guidelines into practice and improving the quality of healthcare regarding women's cervical health and cancer prevention.
©2012 The Author(s) Journal compilation ©2012 American Academy of Nurse Practitioners.
Similar articles
-
The human papillomavirus in women over 40: implications for practice and recommendations for screening.J Am Acad Nurse Pract. 2010 Feb;22(2):92-100. doi: 10.1111/j.1745-7599.2009.00477.x. J Am Acad Nurse Pract. 2010. PMID: 20132367 Review.
-
Human papillomavirus infection and cervical cancer prevention in Japan and Korea.Vaccine. 2008 Aug 19;26 Suppl 12:M30-42. doi: 10.1016/j.vaccine.2008.05.006. Vaccine. 2008. PMID: 18945412
-
Knowledge, attitude and practice in primary and secondary cervical cancer prevention among young adult Italian women.Vaccine. 2012 Mar 9;30(12):2075-82. doi: 10.1016/j.vaccine.2012.01.057. Epub 2012 Jan 31. Vaccine. 2012. PMID: 22300719
-
Cervical cancer screening among women who attend sexually transmitted diseases (STD) clinics: background paper for 2010 STD Treatment Guidelines.Clin Infect Dis. 2011 Dec;53 Suppl 3:S153-9. doi: 10.1093/cid/cir704. Clin Infect Dis. 2011. PMID: 22080268
-
Incorporating human papillomavirus testing into cytological screening in the era of prophylactic vaccines.Best Pract Res Clin Obstet Gynaecol. 2011 Oct;25(5):617-29. doi: 10.1016/j.bpobgyn.2011.05.003. Epub 2011 Jun 17. Best Pract Res Clin Obstet Gynaecol. 2011. PMID: 21683657 Review.
Cited by
-
Application of the Carolina Framework for Cervical Cancer Prevention.Gynecol Oncol. 2014 Mar;132 Suppl 1(0 1):S33-40. doi: 10.1016/j.ygyno.2013.12.004. Epub 2013 Dec 10. Gynecol Oncol. 2014. PMID: 24333357 Free PMC article.
-
Diagnosis of Cervical Cancer based on Ensemble Deep Learning Network using Colposcopy Images.Biomed Res Int. 2021 May 4;2021:5584004. doi: 10.1155/2021/5584004. eCollection 2021. Biomed Res Int. 2021. PMID: 33997017 Free PMC article.
-
Rôle des infirmières praticiennes en soins primaires pour aplanir les obstacles au dépistage du cancer du col: revue de la littérature.Can Oncol Nurs J. 2022 Apr 1;32(2):245-257. doi: 10.5737/23688076322245257. eCollection 2022 Spring. Can Oncol Nurs J. 2022. PMID: 35582259 Free PMC article. French.
-
The role of primary care Nurse Practitioners in reducing barriers to cervical cancer screening: A literature review.Can Oncol Nurs J. 2022 Apr 1;32(2):233-244. doi: 10.5737/23688076322233244. eCollection 2022 Spring. Can Oncol Nurs J. 2022. PMID: 35582261 Free PMC article.
-
Compliance with cervical cancer screening and human papillomavirus testing guidelines among insured young women.Am J Obstet Gynecol. 2013 Sep;209(3):200.e1-7. doi: 10.1016/j.ajog.2013.05.058. Epub 2013 May 30. Am J Obstet Gynecol. 2013. PMID: 23727519 Free PMC article.
